This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Medicaid Drug Rebate Program (MDRP) Summit 2025
September 15-17, 2025
Delivered as a Hybrid EventFairmont Chicago Millennium Park, Chicago, IL

Michael Kvassay
Team Leader, Department of Health and Human Services at HHS Office of Inspector General
Speaker

Profile

Michael Kvassay is a Social Science Analyst and Team Leader in the Baltimore Regional Office of Evaluation and Inspections, a component within the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS). Michael joined OEI in 2015, and recently published a report examining the cost of Stelara—for enrollees with original fee-for-service Medicare Part B and standalone Part D drug plans—when the drug was physician-administered under Part B versus self-administered at home under Part D. Other studies he has worked on include reports evaluating the Centers for Medicare & Medicaid Services’ oversight of reasonable assumptions in the Medicaid Drug Rebate Program, utilization of lower-cost hepatitis C drugs in Medicare Part D, how high-expenditure orphan drugs are being used in Medicare, as well as Federal oversight of child welfare programs.

Agenda Sessions

  • Recent OIG Evaluations Involving Prescription Drug Pricing, Payment, and Coverage – LIVE STREAM

    1:00pm